Athersys, Inc.
The solid gain came after the company and the University of Texas Health Science Center at Houston announced the enrollment of the first patient in a phase 2 clinical study evaluating the company's MultiStem cell therapy as a potential early treatment for traumatic injuries.
The company doesn't have any approved products on the market ye t, so...
ATHX recently broke out of a descending wedge that took it from the top of the channel to the bottom...after 9 weeks of consolidation, it is now trading above all major moving averages...monday saw a break above the 200 day ma and today saw a retest...macd is in positive territory and looks to be holding...target for descending wedge coincides nicely with the top...
